Zealand Pharma A/S Earnings Date & Estimates

Zealand Pharma A/S (OTCMKTS:ZLDPF) is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. Its research is primarily directed toward metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs, often using innovative peptide structures and delivery approaches.

Zealand’s portfolio has included dasiglucagon, a glucagon analogue developed for the treatment of severe hypoglycemia. The product received U.S. approval under the brand name Zegalogue. The company also has development programs targeting obesity and metabolic disease, including investigational treatments such as petrelintide, as well as other earlier-stage peptide candidates. Zealand has historically advanced programs independently and through collaborations with larger pharmaceutical companies.

Founded in 1998, Zealand Pharma is headquartered in Søborg, Denmark, and serves international markets through its own operations and strategic partnerships. The company’s shares are listed on Nasdaq Copenhagen and trade over the counter in the United States under the symbol ZLDPF. Adam Steensberg has served as the company’s president and chief executive officer since 2022.